ClinicalTrials.gg
CompletedNCT03826602Updated Mar 27, 2019

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin

A Phase 1 interventional study of Tucatinib and Metformin in Drug-drug Interaction, sponsored by Seagen Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-27.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2019, 7 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is being done to look at how tucatinib might affect the way another drug (metformin) works. It will look at healthy volunteers and how tucatinib affects how the body absorbs metformin. This will help us find out whether tucatinib is safe to give together with metformin. The study will also look at how tucatinib affects how the kidneys work.

Read the detailed description

This is a single center, fixed-sequence, drug-drug interaction study to assess the effects of multiple oral doses of tucatinib on the pharmacokinetics of a single oral dose of metformin in healthy subjects. The primary objective of the study is to assess the effects of tucatinib on the single-dose PK of metformin. Secondary objectives of the study are to (1) assess the safety and tolerability of metformin when coadministered with tucatinib and (2) assess the effects of tucatinib on renal function using iohexol as glomerular filtration rate (GFR) marker.

02

Conditions studied

  • Drug-drug Interaction
03

In context

Lead sponsor

Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.

Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.

First submitted before Seagen Inc. became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy status, as defined by the absence of evidence of any findings
  • Males must agree to use a barrier method of and not donate sperm during study plus 30 days after last dose of study drug
  • Weight of ≥60kg
  • between 18.0 and 32.0 kg/m² (inclusive)
  • Ability to abstain from alcohol-, caffeine-, and xanthine-containing food and beverages from 48 hours prior to admission through study discharge
  • All nonregular medication (including over-the-counter medication, health supplements, and herbal remedies) must be stopped at least 28 days prior to admission

Exclusion criteria

Exclusion Criteria:

  • Females who are of or lactating
  • Males with female partners who are pregnant, lactating, or planning to become pregnant within 30 days of the study
  • Use of any drug or device within 30 days of study start
  • Use of tobacco products within 21 days prior to admission
  • Routine or chronic use of more than 3 grams of acetaminophen daily
  • Strenuous activity, sunbathing, and contact sports within 72 hours prior to first admission and for the duration of the study
  • Blood transfusion within 90 days of study drug administration
  • History of alcoholism or drug abuse within 2 years
  • History of alcohol consumption exceeding 7 drinks/week for female participants or 14 drinks/week for male subjects
  • History of donation of more than 450 mL of blood within 60 days prior to dosing, or planned donation before 30 days have elapsed since intake of study drug
  • Plasma or donation within 7 days of initial study drug administration
  • Positive screening test for , , or 1 or 2 (human immunodeficiency virus)
  • Acute or chronic metabolic acidosis, including diabetic ketoacidosis
  • Renal disease or dysfunction as suggested by serum creatinine levels or abnormal
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Tucatinib plus metformin

    Tucatinib administered twice daily on Days 2-8. Metformin administered as a single dose on Days 1 and 8. Iohexol administered via IV push on Days 1 and 8

    Drug: Tucatinib · Drug: Metformin · Drug: Iohexol

Interventions

  • 150mg administered orally twice daily

  • 850mg administered orally

  • DrugIohexol

    1500 mg administered intravenously (IV)

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of metformin

    Time frame: Up to 9 days

  2. Time to maximum observed plasma concentration (tmax) of metformin

    Time frame: Up to 9 days

  3. Half-life (t1/2) of metformin

    Time frame: Up to 9 days

  4. Area under the plasma concentration-time curve from time 0 to the last available measurement (AUC0-last) of metformin

    Time frame: Up to 9 days

  5. Area under the plasma concentration time curve to time 0 extrapolated to infinity (AUC0-inf) of metformin

    Time frame: Up to 9 days

  6. Apparent volume of distribution (V2/F) of metformin

    Time frame: Up to 9 days

  7. Oral clearance (CL/F) of metformin

    Time frame: Up to 9 days

Secondary outcomes

  1. Incidence of adverse events (as assessed by AE assessments, clinical laboratory tests, physical examinations, vital signs measurements, and 12-lead electrocardiogram)

    Time frame: Up to 16 days

  2. Glomerular Filtration Rate (GFR) as measured by iohexol plasma clearance

    Time frame: Up to 8 days

07

Study locations

1 site
  • Pharmaceutical Research Associates
    Salt Lake City, Utah 84107, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Mar 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2019
First posted
Feb 1, 2019
StartActual
Feb 12, 2019
Primary completionActual
Mar 8, 2019
CompletionActual
Mar 15, 2019
Last update
Mar 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03826602
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Feb 1, 2019
Start date
Feb 12, 2019
Primary completion
Mar 8, 2019
Completion
Mar 15, 2019
Last update
Mar 27, 2019

Study contacts

JoAl Mayor, PharmD, BCOP
study director · Seagen Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tucatinib · Metformin

Start the discussion